4:58 PM
 | 
Aug 30, 2013
 |  BC Extra  |  Company News

Australia delays Kalydeco reimbursement decision

Australia's Pharmaceutical Benefits Advisory Committee (PBAC) deferred a reimbursement decision on Kalydeco ivacaftor to allow Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) time to submit a new price proposal for the cystic fibrosis (CF) drug. PBAC...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >